276. Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
作者: Robert Haddad.;Jérôme Fayette.;Maria Teixeira.;Kumar Prabhash.;Ricard Mesia.;Andrzej Kawecki.;Arunee Dechaphunkul.;José Dinis.;Ye Guo.;Muneyuki Masuda.;Ching-Yun Hsieh.;Maria Grazia Ghi.;Claudia Vaz de Melo Sette.;Kevin Harrington.;Makoto Tahara.;Nabil F Saba.;Agnes Lau.;Tao Jiang.;Yibing Yan.;Marcus Ballinger.;Monika Kaul.;Christina Matheny.;Vaikunth Cuchelkar.;Deborah J Wong.
来源: JAMA. 2025年333卷18期1599-1607页
Treating locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) involves any combination of surgery, radiation, and chemotherapy, followed by routine monitoring for local recurrence or distant metastases. Given the poor patient outcomes, a significant unmet clinical need for improved treatment options remains.
278. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.
作者: Ye-Lin Liang.;Xu Liu.;Liang-Fang Shen.;Guang-Yuan Hu.;Guo-Rong Zou.;Ning Zhang.;Chuan-Ben Chen.;Xiao-Zhong Chen.;Xiao-Dong Zhu.;Ya-Wei Yuan.;Kun-Yu Yang.;Feng Jin.;Wei-Han Hu.;Fang-Yun Xie.;Ying Huang.;Fei Han.;Ling-Long Tang.;Yan-Ping Mao.;Li-Xia Lu.;Rui Sun.;Yu-Xiang He.;Yang-Ying Zhou.;Guo-Xian Long.;Jie Tang.;Lu-Si Chen.;Jing-Feng Zong.;Ting Jin.;Ling Li.;Jie Lin.;Jing Huang.;Xiu-Yun Gong.;Guan-Qun Zhou.;Lei Chen.;Wen-Fei Li.;Yu-Pei Chen.;Cheng Xu.;Li Lin.;Shao-Hui Huang.;Sai-Wei Huang.;Ya-Qin Wang.;Cheng-Long Huang.;Hui-Xia Feng.;Min Hou.;Chun-Hua Chen.;Su-Fen Zheng.;Ying-Qing Li.;Shu-Bin Hong.;Yu-Sheng Jie.;Hao Li.;Jing-Ping Yun.;Sheng-Bing Zang.;Song-Ran Liu.;Qing-Guang Lin.;Hao-Jiang Li.;Li Tian.;Li-Zhi Liu.;Hong-Yun Zhao.;Ji-Bin Li.;Ai-Hua Lin.;Na Liu.;Yuan Zhang.;Rui Guo.;Jun Ma.;Ying Sun.
来源: JAMA. 2025年333卷18期1589-1598页
Approximately 20% to 30% of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) experience disease relapse despite definitive chemoradiotherapy. The programmed cell death 1 (PD-1) blockade camrelizumab has demonstrated considerable value in recurrent or metastatic NPC, while its role in locoregionally advanced NPC is unclear.
|